Welcome to our dedicated page for UNITEDHEALTH GROUP SEC filings (Ticker: UNH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on UNITEDHEALTH GROUP's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into UNITEDHEALTH GROUP's regulatory disclosures and financial reporting.
UnitedHealth Group Inc. (UNH) director reports initial ownership in a Form 3 filed under Section 16. As of the event date of 11/18/2025, the reporting person lists beneficial ownership of 0 shares of UnitedHealth Group common stock, held directly. No derivative securities are reported in the derivative securities table.
The form is filed by one reporting person in the capacity of director. A power of attorney is on file, with the Form 3 signed by Faraz A. Choudhry as attorney-in-fact for Scott M. Gottlieb.
UnitedHealth Group Incorporated reported that its Board of Directors has appointed Scott Gottlieb, M.D. as an independent director, effective immediately. He has not yet been assigned to any Board committees.
Dr. Gottlieb is a former FDA commissioner who served from 2017 to 2019, where he focused on transparency, patient safety, medical innovation, pharmaceutical competition, the opioid crisis and youth tobacco use. He has also held positions at the Centers for Medicare & Medicaid Services and on the Federal Health Information Technology Policy Committee, and is a physician, a member of the National Academy of Medicine, a senior fellow at the American Enterprise Institute and a partner at New Enterprise Associates.
Dr. Gottlieb currently serves on the boards of Pfizer, Inc., Tempus AI, Inc. and Illumina, Inc. He will receive the company’s standard compensation for non-employee directors as described in UnitedHealth Group’s 2025 proxy statement, and the company will enter into its standard indemnification agreement with him.
UnitedHealth Group amended its Amended and Restated Bylaws, effective November 6, 2025. The sole purpose of the change is to reflect updates to the Company’s registered office and registered agent in the State of Delaware.
A complete copy of the Bylaws, as amended, is filed as Exhibit 3.1.
UnitedHealth Group announced that senior leaders will participate in an interview at the UBS Global Healthcare Conference 2025. The session is scheduled for Monday, November 10, 2025, at 8:45 a.m. Eastern Time.
A live audio webcast will be accessible via the Investor Relations section of the company’s website. The disclosure is furnished under Item 7.01 (Regulation FD) and is not deemed filed under the Securities Exchange Act of 1934.
UnitedHealth Group (UNH) reported Q3 2025 results showing strong top-line growth but significantly lower profitability. Total revenues were $113.2 billion, up 12% year over year, driven by Medicare Advantage growth and Optum Rx volume. Diluted EPS was $2.59 versus $6.51 a year ago as medical costs rose faster than premiums.
Profitability compressed: the medical care ratio increased to 89.9% from 85.2%, reflecting Medicare funding reductions, higher care utilization, and seasonal impacts from the Inflation Reduction Act on Part D. Operating margin fell to 3.8% from 8.6% and earnings from operations declined 50% to $4.3 billion.
Segment trends: UnitedHealthcare revenue grew 16% with 795,000 more people served, primarily in Medicare Advantage. Optum revenues rose 8% (Optum Rx up 16%), while Optum Health profitability was pressured by Medicare dynamics and elevated cost trends. For the nine months, cash flows from operations were $18.6 billion, supporting ongoing dividends and repurchases disclosed in the period.
UnitedHealth Group (UNH) furnished an 8-K announcing its third quarter 2025 results. The company disclosed that it issued a press release detailing Q3 2025 performance, which is provided as Exhibit 99.1 and incorporated by reference.
The disclosure under Item 2.02 is expressly stated as furnished and not deemed filed under the Exchange Act. The filing also includes the Cover Page Interactive Data File labeled as Exhibit 104.
Frederick W. McNabb III, a director of UnitedHealth Group Inc. (UNH), reported receipt of 289 deferred stock units as compensation on 10/01/2025. The units were issued at $0 and are immediately vested but must be retained until he leaves the Board. Following the grant, Mr. McNabb beneficially owns 14,341 shares (direct). The Form 4 was signed by an attorney-in-fact on 10/03/2025.
Timothy P. Flynn, a director of UnitedHealth Group Inc. (UNH), received 272 deferred stock units on 10/01/2025 as regular quarterly director compensation at a reported price of $0. The filing shows 9,810 shares beneficially owned following the transaction and an additional 6,033 shares held indirectly by trust. The form explains these deferred stock units are immediately vested but must be retained until the director leaves the board. The Form 4 was signed by an attorney-in-fact and dated 10/03/2025.
UnitedHealth Group (UNH) director Kristen L. Gil received 162 shares of common stock as regular quarterly director compensation on 10/01/2025 at no cash price reported. After the grant, Ms. Gil directly beneficially owns 1,900 shares and indirectly owns 3,800 shares through a trust. The Form 4 was signed by an attorney-in-fact on 10/03/2025. The filing identifies the reporting person as a director and notes the shares were granted as routine director compensation.
UnitedHealth Group (UNH) director Valerie C. Montgomery Rice, M.D. was granted 270 deferred stock units on 10/01/2025 as part of regular quarterly director compensation. The units are immediately vested but must be held until she leaves the board. After the grant, her reported beneficial ownership of common stock is 6,897 shares, held directly. The Form 4 was signed by an attorney-in-fact on 10/03/2025.